{"id":62269,"date":"2023-12-26T09:00:57","date_gmt":"2023-12-26T14:00:57","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=62269"},"modified":"2024-10-25T10:20:49","modified_gmt":"2024-10-25T14:20:49","slug":"patient-questions-about-insulin-biosimilars","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/patient-questions-about-insulin-biosimilars\/","title":{"rendered":"6 common patient questions about insulin biosimilars"},"content":{"rendered":"

For many patients with diabetes, particularly those with Type 1 diabetes, insulin is a key part of managing glucose levels and preventing complications. However, many patients may have trouble getting the insulin they need, whether due to high costs or limited options. While many brand-name medications are widely available as cheaper generic alternatives, such options are often <\/span>less accessible<\/span><\/a> for insulin products.<\/span><\/p>\n

With insulin now being categorized as a biologic product, the development of insulin biosimilars has gained momentum. These biosimilar products are highly similar to their reference insulin products and have no clinically meaningful differences in terms of safety and efficacy. However, many patients may not be familiar with biologic products, biosimilars, and interchangeable biologic drugs. <\/span><\/p>\n

6 common patient questions about insulin biosimilars<\/span><\/h2>\n

Read on to explore insulin biosimilar medications and how to answer common patient questions about them. <\/span><\/p>\n

1. Is insulin a biologic medication?<\/span><\/h3>\n

Yes, as of <\/span>March 2020<\/span><\/a>, insulin is considered a biologic product by the FDA. Biologic medications are derived from living organisms and include a wide range of prescriptions used to treat different medical conditions, such as cancer and diabetes. Unlike chemically synthesized drugs, biologic products are more complex in how they’re manufactured.<\/span><\/p>\n

The change from insulin as a drug to a biologic has paved the way for the development of biosimilar products. As a result, the market for insulin should see increased competition and potentially lower costs for insulin products. <\/span><\/p>\n

2. What are insulin biosimilars?<\/span><\/h3>\n

Insulin biosimilars are medications that are highly similar in structure to insulin biologics and are as effective as the original products, also known as reference products. Insulin biosimilars work similarly to generic drugs, offering a more <\/span>cost-effective alternative<\/span><\/a> without compromising on efficacy or safety. In addition, the names of biosimilars are typically designated with four letters after the reference product names to differentiate the biosimilars. <\/span><\/p>\n

3. Are insulin biosimilars available?<\/span><\/h3>\n

Currently, available insulin biosimilars on the market include:<\/span><\/p>\n